- Home
- CURR vs DERM Comparison
CURR vs DERM Comparison
Compare CURR & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURR
- DERM
- Stock Information
- Founded
- CURR 2013
- DERM 2014
- Country
- CURR Singapore
- DERM United States
- Employees
- CURR N/A
- DERM N/A
- Industry
- CURR Business Services
- DERM Biotechnology: Pharmaceutical Preparations
- Sector
- CURR Consumer Discretionary
- DERM Health Care
- Exchange
- CURR Nasdaq
- DERM Nasdaq
- Market Cap
- CURR 151.4M
- DERM 165.6M
- IPO Year
- CURR N/A
- DERM 2021
- Fundamental
- Price
- CURR $1.60
- DERM $7.17
- Analyst Decision
- CURR Strong Buy
- DERM Strong Buy
- Analyst Count
- CURR 1
- DERM 3
- Target Price
- CURR $3.50
- DERM $12.67
- AVG Volume (30 Days)
- CURR 162.0K
- DERM 142.5K
- Earning Date
- CURR 08-04-2025
- DERM 11-11-2025
- Dividend Yield
- CURR N/A
- DERM N/A
- EPS Growth
- CURR N/A
- DERM N/A
- EPS
- CURR N/A
- DERM N/A
- Revenue
- CURR $41,092,419.00
- DERM $56,397,000.00
- Revenue This Year
- CURR N/A
- DERM $28.10
- Revenue Next Year
- CURR $14.56
- DERM $53.84
- P/E Ratio
- CURR N/A
- DERM N/A
- Revenue Growth
- CURR N/A
- DERM N/A
- 52 Week Low
- CURR $0.33
- DERM $3.54
- 52 Week High
- CURR $7.08
- DERM $8.90
- Technical
- Relative Strength Index (RSI)
- CURR 50.53
- DERM 51.42
- Support Level
- CURR N/A
- DERM N/A
- Resistance Level
- CURR $1.71
- DERM $7.12
- Average True Range (ATR)
- CURR 0.12
- DERM 0.25
- MACD
- CURR -0.08
- DERM -0.26
- Stochastic Oscillator
- CURR 88.61
- DERM 95.47
About CURR Currenc Group Inc. Ordinary Shares
Currenc Group Inc is a fintech pioneer dedicated to transforming financial services through artificial intelligence (AI). It empowers financial institutions with comprehensive AI solutions, including the SEAMLESS AI Call Centre and other AI-powered tools designed to reduce costs, increase efficiency, and boost customer satisfaction. The Company's digital remittance platform also enables e-wallets, remittance companies, and corporations to provide real-time, 24/7 payment services, advancing financial access across underserved communities. It generates the majority of its geographic revenue from Malaysia.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.